To verify CeO2 NPs exerted mutp53 degradation in vivo, we also assessed p53 expression level in tumor sections obtained at the end of the treatment period evaluated by immunohistochemistry analysis and western blotting. The gene discussed is TP53; the disease is neoplasm.